Press Releases

 
Press Releases
  Date Title and Summary View
Feb 22, 2017
CRANBURY, N.J., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced a conference call and live audio webcast on Wednesday, March 1, 2017 at 8:30 a.m. ET to discuss financial results for the year ended December 31, 2016. ...
PDF
Feb 15, 2017
Biomarkers of Muscle Damage (AST, ALT and CK) Demonstrate Improving Trends in Majority of Patients Biomarker of Key Disease Substrate (Hex4) Demonstrates Improving Trend in All Patients Safety Data Continue to Show No Infusion-AssociatedReactions Following 150+ Infusions CRANBURY, N.J. and SAN DIEGO, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Ami...
PDF
Feb 15, 2017
Scientific Findings Reveal that Cellular Damage Alters Trafficking for Key Proteins Involved in Muscle Membrane Integrity and Muscle Repair Preclinical Studies Demonstrate Reversal of Cellular Damage and Significant Improvements in Muscle Strength in GAA Knock-out Mice After Treatment with Amicus Novel Pompe Treatment Paradigm Additional ...
PDF
Feb 14, 2017
New Phase 3 Retrospective Analysis Shows Correlation between Reduction in Disease Substrate (Kidney Interstitial Capillary GL-3) and Improved Diarrhea in Fabry Patients with Amenable Mutations treated with Migalastat Supportive Study for Japanese New Drug Application (J-NDA) Demonstrates Migalastat Exposure is Similar in Japanese and non-Japan...
PDF
Feb 6, 2017
CRANBURY, N.J., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will participate in a corporate overview and fireside chat at the Leerink Partners 6th Annual Global Healthcare Co...
PDF
Jan 24, 2017
CRANBURY, N.J., Jan. 24, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that 3 oral presentations and 9 posters highlighting its development programs for Lysosomal Storage Disorders will be included at the 13th Annual WORLDSympo...
PDF
Jan 9, 2017
Strong Momentum for Galafold Launch in Europe and Multiple Global Regulatory Submissions Ahead Additional Data from Pompe Phase 1/2 Clinical Study and Top-Line Data from Phase 3 Epidermolysis Bullosa Study Expected in 2017 $331M Cash Balance with Runway Into 2H18 CRANBURY, N.J., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (...
PDF
Jan 4, 2017
Reimbursement Secured for Patients in England Commercial Launch in England, Wales and Northern Ireland Anticipated in Early 2017 CRANBURY, N.J., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that the National Institute for Hea...
PDF
Dec 23, 2016
CRANBURY, N.J., Dec. 23, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 35th Annual J.P. Morgan Healthcare Conference in San Fr...
PDF
Dec 21, 2016
CRANBURY, N.J., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, announced the closing of its previously announced private offering of $250 million aggregate principal amount of 3.00% convertible senior notes due 2023 (the "notes"), including the full...
PDF
Page:
1
... NextLast